Suppr超能文献

舒更葡糖钠与新斯的明用于导管介入神经治疗患者罗库溴铵神经肌肉阻滞逆转的随机试验

Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-Based Neurointerventional Procedures: A Randomized Trial.

作者信息

Farag Ehab, Rivas Eva, Bravo Mauro, Hussain Shazam, Argalious Maged, Khanna Sandeep, Seif John, Pu Xuan, Mao Guangmei, Bain Mark, Elgabaly Mohamed, Esa Wael Ali Sakr, Sessler Daniel I

机构信息

From the Department of Outcomes Research.

Department of General Anesthesia, Cleveland Clinic, Cleveland, Ohio.

出版信息

Anesth Analg. 2021 Jun 1;132(6):1666-1676. doi: 10.1213/ANE.0000000000005533.

Abstract

BACKGROUND

Catheter-based endovascular neurointerventions require deep neuromuscular blocks during the procedure and rapid subsequent recovery of strength to facilitate neurological evaluation. We tested the primary hypothesis that sugammadex reverses deep neuromuscular blocks faster than neostigmine reverses moderate neuromuscular blocks.

METHODS

Patients having catheter-based cerebral neurointerventional procedures were randomized to: (1) deep rocuronium neuromuscular block with posttetanic count 1 to 2 and 4-mg/kg sugammadex as the reversal agent or (2) moderate rocuronium neuromuscular block with train-of-four (TOF) count 1 during the procedure and neuromuscular reversal with 0.07-mg/kg neostigmine to a maximum of 5 mg. Recovery of diaphragmatic function was assessed by ultrasound at baseline before the procedure and 90 minutes thereafter. The primary outcome-time to reach a TOF ratio ≥0.9 after administration of the designated reversal agent-was analyzed with a log-rank test. Secondary outcomes included time to successful tracheal extubation and the difference between postoperative and preoperative diaphragmatic contraction speed and distance.

RESULTS

Thirty-five patients were randomized to sugammadex and 33 to neostigmine. Baseline characteristics and surgical factors were well balanced. The median time to reach TOF ratio ≥0.9 was 3 minutes (95% confidence interval [CI], 2-3 minutes) in patients given sugammadex versus 8 minutes (95% CI, 6-10 minutes) in patients given neostigmine. Sugammadex was significantly faster by a median of 5 minutes (95% CI, 3-6 minutes; P < .001). However, times to tracheal extubation and diaphragmatic function at 90 minutes did not differ significantly.

CONCLUSIONS

Sugammadex reversed deep rocuronium neuromuscular blocks considerably faster than neostigmine reversed moderate neuromuscular blocks. However, times to extubation did not differ significantly, apparently because extubation was largely determined by the time required for awaking from general anesthesia and because clinicians were willing to extubate before full neuromuscular recovery. Sugammadex may nonetheless be preferable to procedures that require a deep neuromuscular block and rapid recovery.

摘要

背景

基于导管的血管内神经介入手术在操作过程中需要深度神经肌肉阻滞,并在术后迅速恢复肌力以利于神经功能评估。我们检验了主要假设,即舒更葡糖钠逆转深度神经肌肉阻滞的速度比新斯的明逆转中度神经肌肉阻滞的速度更快。

方法

接受基于导管的脑血管介入手术的患者被随机分为:(1)给予深度罗库溴铵神经肌肉阻滞,强直刺激后计数为1至2,并用4mg/kg舒更葡糖钠作为逆转剂;或(2)给予中度罗库溴铵神经肌肉阻滞,术中四个成串刺激(TOF)计数为1,并用0.07mg/kg新斯的明进行神经肌肉逆转,最大剂量为5mg。在术前基线及术后90分钟通过超声评估膈肌功能恢复情况。主要结局指标——给予指定逆转剂后达到TOF比值≥0.9的时间——采用对数秩检验进行分析。次要结局指标包括成功气管拔管的时间以及术后与术前膈肌收缩速度和距离的差值。

结果

35例患者被随机分配至舒更葡糖钠组,33例被分配至新斯的明组。基线特征和手术因素均衡良好。给予舒更葡糖钠的患者达到TOF比值≥0.9的中位时间为3分钟(95%置信区间[CI],2 - 3分钟),而给予新斯的明的患者为8分钟(95%CI,6 - 10分钟)。舒更葡糖钠明显更快,中位时间快5分钟(95%CI,3 - 6分钟;P <.001)。然而,气管拔管时间和90分钟时的膈肌功能并无显著差异。

结论

舒更葡糖钠逆转深度罗库溴铵神经肌肉阻滞的速度比新斯的明逆转中度神经肌肉阻滞的速度快得多。然而,拔管时间并无显著差异,显然是因为拔管很大程度上取决于全身麻醉苏醒所需时间,且临床医生愿意在神经肌肉功能完全恢复前进行拔管。尽管如此,对于需要深度神经肌肉阻滞和快速恢复的手术,舒更葡糖钠可能更具优势。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验